Physician profile
Michael Knox
NPI 1518160910
$3,952.44
in general payments reported to CMS, 2019-2025
37 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $269 · 2021: $387 · 2022: $762 · 2023: $562 · 2024: $319 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $563.26 | 2019-2025 | Ams 700, Axonics, Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $539.24 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $440.70 | 2019-2025 | Xtandi, Myrbetriq |
| Intuitive Surgical, INC. | $405.44 | 2019-2025 | |
| Procept Biorobotics Corporation | $318.19 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Pfizer INC. | $168.23 | 2019-2025 | |
| Axonics, INC. | $136.48 | 2021-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $123.80 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $111.38 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $107.95 | 2019-2022 | |
| Coloplast Corp | $99.54 | 2019-2024 | |
| 180 Medical, INC. | $90.24 | 2019-2025 | |
| Urogen Pharma, INC. | $80.81 | 2022-2025 | |
| Ethicon US, LLC | $64.11 | 2021-2023 | Echelon; Endopath |
| Urovant Sciences INC | $59.82 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.